Log in to your Inderes Free account to see all free content on this page.
Swedish Orphan Biovitrum
309.2
SEK
+1.64 %
SOBI
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
4 following
+1.64%
-6.13%
-0.13%
+8.72%
+15.81%
+23.38%
+88.75%
+110.82%
+547.97%
www.sobi.com/en/investors
Swedish Orphan Biovitrum, also known as Sobi, is an international pharmaceutical company. The company is focused on the research and development of treatments and belonging services for patients with rare diseases. The products are mainly focused on the treatment of inflammatory and genetic diseases. Sobi also markets specialized wound patches under various brands. The head office is located in Stockholm.
Revenue
22.12B
EBIT %
18.38 %
P/E
41.39
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SOBI
Daily low / high price
302.8 / 310
SEK
Market cap
110.08B SEK
Turnover
82.69M SEK
Volume
268K
Financial calendar
Extraordinary general meeting
11.12.2024
Annual report
05.02.2025
Interim report
29.04.2025
General meeting
08.05.2025
Interim report
15.07.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Investor | 34.5 % | 34.5 % |
| Morgan Stanley Smith Barney | 9.8 % | 9.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Swedish Orphan Biovitrum AB: David Meek is proposed as new Chair of the Board of Directors of Sobi
Swedish Orphan Biovitrum AB: New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio